Dyne Therapeutics Announces Pricing of $200.0 Million Public Offering of Common Stock

Rhea-AI Summary

Dyne Therapeutics (NASDAQ: DYN), a clinical-stage company specializing in genetically driven neuromuscular diseases, has announced the pricing of a public offering of 24,242,425 shares of its common stock at $8.25 per share. The offering is expected to generate gross proceeds of $200.0 million before deducting underwriting discounts and commissions.

The company has granted underwriters a 30-day option to purchase up to an additional 3,636,363 shares at the public offering price, less underwriting discounts and commissions. The offering is expected to close around July 2, 2025. Morgan Stanley, Jefferies, Stifel, and Guggenheim Securities are serving as joint book-running managers, with Jones acting as co-manager.

[ "Expected gross proceeds of $200.0 million to strengthen company's financial position", "Additional potential proceeds through 30-day option for underwriters to purchase extra shares", "Strong institutional backing with multiple prominent investment banks as joint book-running managers" ]

Positive

• None.

Negative

• Significant dilution for existing shareholders with 24.2 million new shares being issued
• Additional potential dilution if underwriters exercise their option for 3.6 million more shares

News Market Reaction

-8.82%

1 alert

-8.82% News Effect

On the day this news was published, DYN declined 8.82%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

WALTHAM, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the pricing of an underwritten public offering of 24,242,425 shares of its common stock at a public offering price of $8.25 per share. The gross proceeds to Dyne from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Dyne, are expected to be $200.0 million. All shares in the offering are being sold by Dyne. The offering is expected to close on or about July 2, 2025, subject to customary closing conditions. In addition, Dyne has granted the underwriters a 30-day option to purchase up to an additional 3,636,363 shares of its common stock at the public offering price, less the underwriting discounts and commissions.

Morgan Stanley, Jefferies, Stifel and Guggenheim Securities are acting as joint book-running managers for the offering. Jones is acting as co-manager for the offering.

The offering is being made pursuant to a shelf registration statement on Form S-3 that was previously filed with the Securities and Exchange Commission (“SEC”) on March 5, 2024 and became automatically effective upon filing. This offering is being made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement. A preliminary prospectus supplement relating to and describing the terms of the offering has been filed with the SEC and may be obtained for free by visiting the SEC’s website at www.sec.gov. A final prospectus supplement relating to the offering will be filed with the SEC. When available, copies of the final prospectus supplement and the accompanying prospectus may also be obtained by contacting: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or by email at prospectus@morganstanley.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; Stifel, Nicolaus & Company, Incorporated, Attention: Prospectus Department, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com.   

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Dyne Therapeutics

Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease.

Forward-Looking Statements  

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements relating to the anticipated closing date of the public offering, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “predict,” “project,” “potential,” “should,” or “would,” or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Dyne may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including the risks and uncertainties related to the satisfaction of customary closing conditions for the public offering and other factors discussed in the “Risk Factors” section of the preliminary prospectus supplement filed with the SEC on June 30, 2025, as well as the risks and uncertainties identified in Dyne’s filings with the SEC, including Dyne’s most recent Form 10-Q and in subsequent filings Dyne may make with the SEC. In addition, the forward-looking statements included in this press release represent Dyne’s views as of the date of this press release. Dyne anticipates that subsequent events and developments will cause its views to change. However, while Dyne may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Dyne’s views as of any date subsequent to the date of this press release.

Contacts:

Investors

Mia Tobias
ir@dyne-tx.com
781-317-0353

Media

Stacy Nartker
snartker@dyne-tx.com
781-317-1938

FAQ

What is the size and price of Dyne Therapeutics' (DYN) public offering in 2025?

Dyne Therapeutics is offering 24,242,425 shares at $8.25 per share, aiming to raise $200.0 million in gross proceeds.

When will Dyne Therapeutics' (DYN) 2025 public offering close?

The offering is expected to close on or about July 2, 2025, subject to customary closing conditions.

Who are the underwriters for Dyne Therapeutics' (DYN) 2025 public offering?

Morgan Stanley, Jefferies, Stifel, and Guggenheim Securities are acting as joint book-running managers, with Jones as co-manager.

What additional options do the underwriters have in DYN's 2025 offering?

Underwriters have a 30-day option to purchase up to 3,636,363 additional shares at the public offering price, less underwriting discounts and commissions.

What is Dyne Therapeutics' (DYN) business focus?

Dyne Therapeutics is a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases.